vs
Side-by-side financial comparison of REED'S, INC. (REED) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $7.5M, roughly 1.8× REED'S, INC.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -50.5%, a 126.2% gap on every dollar of revenue. Xilio Therapeutics, Inc. produced more free cash flow last quarter ($-2.1M vs $-3.9M).
Waddell & Reed Financial, Inc. was an American asset management and financial planning company founded in 1937 in Kansas City, Missouri. It was a publicly traded company from 1998 to 2021, and briefly had its headquarters in Overland Park, Kansas, and was planning a move back to Downtown Kansas City before the company was sold. It operated asset management and distribution subsidiaries, including Ivy Investment Management Company and Waddell & Reed Investment Management Company.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
REED vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.5M | $13.7M |
| Net Profit | $-3.8M | $10.4M |
| Gross Margin | 20.4% | — |
| Operating Margin | -46.9% | -86.5% |
| Net Margin | -50.5% | 75.7% |
| Revenue YoY | -23.1% | — |
| Net Profit YoY | 8.2% | 179.1% |
| EPS (diluted) | $-1.26 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.5M | $13.7M | ||
| Q3 25 | $7.0M | $19.1M | ||
| Q2 25 | $9.5M | $8.1M | ||
| Q1 25 | $10.0M | $2.9M | ||
| Q4 24 | $9.7M | — | ||
| Q3 24 | $6.8M | — | ||
| Q2 24 | $11.9M | — | ||
| Q1 24 | $9.6M | — |
| Q4 25 | $-3.8M | $10.4M | ||
| Q3 25 | $-4.0M | $-16.3M | ||
| Q2 25 | $-6.0M | $-15.8M | ||
| Q1 25 | $-2.0M | $-13.3M | ||
| Q4 24 | $-4.1M | — | ||
| Q3 24 | $-4.2M | — | ||
| Q2 24 | $-3.2M | — | ||
| Q1 24 | $-1.7M | — |
| Q4 25 | 20.4% | — | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 8.5% | — | ||
| Q1 25 | 33.9% | — | ||
| Q4 24 | 30.0% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | 32.3% | — | ||
| Q1 24 | 35.6% | — |
| Q4 25 | -46.9% | -86.5% | ||
| Q3 25 | -58.3% | -10.1% | ||
| Q2 25 | -60.8% | -177.7% | ||
| Q1 25 | -17.4% | -472.7% | ||
| Q4 24 | -37.6% | — | ||
| Q3 24 | -46.5% | — | ||
| Q2 24 | -5.6% | — | ||
| Q1 24 | -6.8% | — |
| Q4 25 | -50.5% | 75.7% | ||
| Q3 25 | -56.6% | -85.4% | ||
| Q2 25 | -63.5% | -196.0% | ||
| Q1 25 | -20.3% | -452.7% | ||
| Q4 24 | -42.3% | — | ||
| Q3 24 | -61.5% | — | ||
| Q2 24 | -27.1% | — | ||
| Q1 24 | -17.4% | — |
| Q4 25 | $-1.26 | $-3.74 | ||
| Q3 25 | $-0.48 | $-0.11 | ||
| Q2 25 | $-0.13 | $-0.16 | ||
| Q1 25 | $-0.04 | $-0.18 | ||
| Q4 24 | $-3.73 | — | ||
| Q3 24 | $-4.91 | — | ||
| Q2 24 | $-0.77 | — | ||
| Q1 24 | $-0.40 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.2M | $35.3M |
| Total Assets | $23.3M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $9.2M | $35.3M | ||
| Q3 25 | $2.8M | $-8.1M | ||
| Q2 25 | $1.7M | $7.1M | ||
| Q1 25 | $4.7M | $10.7M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $-22.0M | — | ||
| Q2 24 | $-23.8M | — | ||
| Q1 24 | $-20.7M | — |
| Q4 25 | $23.3M | $154.7M | ||
| Q3 25 | $19.9M | $133.7M | ||
| Q2 25 | $23.7M | $133.8M | ||
| Q1 25 | $24.5M | $103.7M | ||
| Q4 24 | $25.1M | — | ||
| Q3 24 | $15.0M | — | ||
| Q2 24 | $18.7M | — | ||
| Q1 24 | $19.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.8M | $-2.0M |
| Free Cash FlowOCF − Capex | $-3.9M | $-2.1M |
| FCF MarginFCF / Revenue | -52.0% | -15.3% |
| Capex IntensityCapex / Revenue | 1.1% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $-17.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.8M | $-2.0M | ||
| Q3 25 | $-2.8M | $-17.5M | ||
| Q2 25 | $-5.0M | $-14.5M | ||
| Q1 25 | $-5.4M | $29.0M | ||
| Q4 24 | $-3.9M | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-912.0K | — | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | $-3.9M | $-2.1M | ||
| Q3 25 | $-2.9M | — | ||
| Q2 25 | $-5.1M | $-14.9M | ||
| Q1 25 | $-5.4M | $29.0M | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $-924.0K | — | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | -52.0% | -15.3% | ||
| Q3 25 | -41.5% | — | ||
| Q2 25 | -53.2% | -184.0% | ||
| Q1 25 | -54.2% | 988.3% | ||
| Q4 24 | -40.8% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | -7.8% | — | ||
| Q1 24 | -25.1% | — |
| Q4 25 | 1.1% | 0.7% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 0.2% | 5.0% | ||
| Q1 25 | 0.7% | 0.8% | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.2% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
